AI Robotics in Medicine

AI in healthcare is shifting into clinical use: FDA-cleared intraoperative imaging brings margin assessment into the OR, MRI-guided incision-free systems are already in procedures, and Profound’s LOIs with Telix target PSMA PET-guided prostate cancer workflows.

The tension is traction versus balance-sheet risk—Profound reported US$18. 8M revenue but a US$7.

05M Q1 2026 loss and reliance on borrowing; Perimeter’s ~US$2. 1M imaging revenue is all from Canada; Eastwood made CA$0.

8M mostly in Asia, is applying AI to a large herbal prescription dataset with BioNexus, and carries negative shareholders’ equity.

Watch whether FDA clearance and the Profound–Telix LOIs convert to commercial uptake, and how financing constraints shape deployment across surgery, imaging, and research.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

1. Profound-Telix LOIs and FDA-cleared imaging underscore AI’s clinical traction

A new screen highlights three AI-in-healthcare companies showing real-world traction across surgery, imaging, and research.

Perimeter Medical Imaging AI’s Claire OCT with ImgAssist AI has U.S. FDA premarket approval for breast-conserving surgery, bringing intraoperative tissue-margin assessment into the operating room.

Profound Medical’s MRI-guided, incision-free systems are already used for procedures, and letters of intent with Telix Pharmaceuticals target PSMA PET–guided prostate cancer workflows. Profound generated US$18.

8 million in revenue, mostly from the U.S., but reported a US$7. 05 million loss in Q1 2026 and relies on external borrowing.

Perimeter booked about US$2. 1 million in imaging revenue, all from Canada; Eastwood Bio-Medical Canada made CA$0.

8 million, mostly from Asia, and is applying AI to a large herbal prescription dataset with BioNexus. Eastwood carries negative shareholders’ equity, heightening financial pressure.

Key facts:

- Perimeter Medical’s Claire OCT with ImgAssist AI has U.S. FDA premarket approval for breast surgery.

- Profound Medical posted US$18.8 million revenue, mostly U.S., and signed Telix workflow collaboration LOIs.

- Eastwood Bio-Medical made CA$0.8 million revenue and is applying AI to herbal prescriptions with BioNexus.

- Profound Medical reported a US$7.05 million loss in Q1 2026 and relies on external borrowing.

Why it matters: AI tools are moving from roadmaps into operating rooms and therapy suites, targeting efficiency, cost savings, and better outcomes under tight public budgets and aging populations.

Perimeter’s FDA-cleared intraoperative imaging and Profound’s MRI-guided ultrasound show clinical integration beyond pilot projects. For investors and providers, execution risk looms large.

Profound’s reliance on external borrowing and Eastwood’s negative equity underline funding constraints, while commercialization pace will determine durability of adoption.

Watch whether the Profound–Telix workflow pilots materialize and how quickly Perimeter scales hospital deployments.

Simplywall